Sepsis: The Systemic Inflammatory Response

Critical Care

Volumn , Issue , 2005, Pages 3-10

  Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882879346     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-02262-0.50005-1     Document Type: Chapter

References (16)

1. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002, 28:108-121.
2. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31:1-11.
3. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871.
4. Appoloni O, Dupont E, Andrien M, et al. Association of TNF2, a TNFα promoter polymorphism, with plasma TNFα levels and mortality in septic shock. Am J Med 2001, 110:486-488.
5. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
6. Bossink AW, Groeneveld J, Hack CE, et al. Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria?. Chest 1998, 113:1533-1541.
7. Eachempati SR, Hydo L, Barie PS Gender-based differences in outcome in patients with sepsis. Arch Surg 1999, 134:1342-1347.
8. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758.
9. Hotchkiss RS, Karl IE Pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
10. Joyce DE, Grinnell BW Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kB. Crit Care Med 2002, 30:S288-S293.
11. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256.
12. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
13. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Meeting Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
14. Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
15. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
16. Wichmann MW, Inthorn D, Andress HJ, et al. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 2000, 26:167-172.